Early detection of Circulating tumor DNA - Medicircle


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Tumors are made up of cells, and at the center of those cells is DNA. As cancer cells go through their life cycle, fragments of DNA can enter the bloodstream.

Human DNA holds the entirety of a person's life. Our DNA is the guide on which we develop, survive, and thrive. Made up of many elements, DNA holds great importance in a human’s life. From the color of our hair to the diseases we’ll suffer, DNA has all this information coded in itself. of the human. Science is usually filled with jargon, which makes many people lose interest in it. But there are many ways in which science and all its mysteries can be accessed in an interesting way.

 It takes many elements to create a human and DNA holds an important part of the human,  Usually, people make science so difficult when there are so many easy ways to discover and have an interest in science. 

Circulating tumor DNA can spread in the bloodstream

DNA released into the bloodstream by tumor cells and carrying the tumor's mutations is called circulating tumor DNA (ctDNA). In recent years, liquid biopsy based on ctDNA analysis has shed new light on cancer molecular diagnosis and monitoring. Using ctDNA to screen for genetic mutations is highly sensitive and specific, implying that ctDNA analysis could significantly improve current tumor diagnosis systems, even facilitating early-stage detection.  that the screening of genetic mutations using ctDNA is highly sensitive and specific, suggesting that ctDNA analysis may significantly improve current systems of tumor diagnosis, even facilitating early-stage detection. Moreover, ctDNA analysis is capable of accurately determining the tumor progression, and prognosis and assisting in targeted therapy.

Circulating Tumor DNA are cancer cells that split away from the primary tumor and appear in the circulatory system as singular units or clusters

Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to DNA that comes from cancerous cells and tumors. Most DNA is inside a cell’s nucleus. As a tumor grows, cells die and are replaced by new ones. The dead cells get broken down and, including DNA, are released into the bloodstream. ctDNA are small pieces of DNA, usually comprising fewer than 200 building blocks (nucleotides) in length.

The quantity of ctDNA varies among individuals and depends on the type of tumor, its location, and for cancerous tumors, the cancer stage.

Detection of ctDNA can be helpful in the following cases:

  • A tumor can be detected and diagnosed. Due to the presence of multiple genetic variants, tumor DNA does not match the individual's DNA exactly. Tumor DNA with genetic differences can be detected. When ctDNA is used to diagnose the type of tumor, it reduces the need for obtaining a sample of tumor tissue (tumor biopsy), which is challenging when the tumor is difficult to reach, such as when it is in the brain or lungs.
  • Providing tumor-specific treatment. Doctors can determine the most effective treatment by analyzing the ctDNA of tumor cells. Currently, however, the Food and Drug Administration for ctDNA testing to personalize cancer treatment is limited.
  • The treatment is being monitored. ctDNA decrease indicates that the tumor is shrinking and the treatment is working.
  • Keeping an eye on remissions (absence of cancer symptoms). The absence of ctDNA in the bloodstream indicates that cancer has not returned.

Circulating tumor cells (CTCs) have been observed in the patient's bloodstream. CTCs are believed to reach a patient’s plasma by migration from the principal or metastatic tumor site secondary to tumor invasion, shedding, or after the tumor site experiences mechanical stress after surgery. Analysis of both CTC and circulating tumor DNA (ctDNA) is the backbone of the development of liquid biopsy.

In recent years, liquid biopsy based on ctDNA analysis has shed new light on cancer molecular diagnosis and monitoring. Using ctDNA to screen for genetic mutations is highly sensitive and specific, implying that ctDNA analysis could significantly improve current tumor diagnosis systems, even facilitating early-stage detection. 

Tags : #Earlydetection #Circulatingtumordna #bloodstream #biopsy-based #liquidbiopsy-based #health #medicircle #smitakumar

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Smart Operating Rooms: The Future of Hospital OTNovember 21, 2026
Smartphone Diagnostics: Phones as Medical Screening ToolsNovember 21, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026